BHP Shares Fall as Jansen Potash Project Costs Surge 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has commenced in the United States District Court for the District of Maryland against Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (Nasdaq:OSIR) on behalf all persons or entities who purchased Osiris securities between May 12, 2014 and November 20, 2015, inclusive (the “Class Period”).
Shareholders who incurred losses on shares purchased within the Class Period are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774.
If you purchased the shares of Osiris Therapeutics, Inc., you may, no later than January 22, 2016, request that the Court appoint you lead plaintiff of the proposed class.
On November 16, 2015, the Company surprised investors by disclosing that it had “determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenue of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014.”
Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com. All e-mail correspondence should make reference to the “Osiris Investigation.”
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Patrick Donovan, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
